Johnson & Johnson (NYSE: JNJ) reported first-quarter 2022 financial results before the regular market hours on Tuesday. The pharmaceutical giant reported revenue of $23.4 billion, up 5% year-over-year, with operational growth of 7.7% Net earnings of $5.1 billion or $1.93 per share decreased by 17%, compared to the previous year.
Johnson & Johnson (NYSE: JNJ) reported first-quarter 2022 financial results before the regular market hours on Tuesday. The pharmaceutical giant reported revenue of $23.4 billion, up 5% year-over-year, with operational growth of 7.7% Net earnings of $5.1 billion or $1.93 per share decreased by 17%, compared to the previous year.
Johnson & Johnson (NYSE: JNJ) reported first-quarter 2022 financial results before the regular market hours on Tuesday.
The pharmaceutical giant reported revenue of $23.4 billion, up 5% year-over-year, with operational growth of 7.7%
Net earnings of $5.1 billion or $1.93 per share decreased by 17%, compared to the previous year.
